Genomic Approach to Identification of Mutations Affecting Caspofungin Susceptibility in Saccharomyces cerevisiae

ABSTRACT The antifungal agent caspofungin (CAS) specifically interferes with glucan synthesis and cell wall formation. To further study the cellular processes affected by CAS, we analyzed a Saccharomyces cerevisiae mutant collection (4,787 individual knockout mutations) to identify new genes affecting susceptibility to the drug. This collection was screened for increased CAS sensitivity (CAS-IS) or increased CAS resistance (CAS-IR). MICs were determined by the broth microdilution method. Disruption of 20 genes led to CAS-IS (four- to eightfold reductions in the MIC). Eleven of the 20 genes are involved in cell wall and membrane function, notably in the protein kinase C (PKC) integrity pathway (MID2, FKS1, SMI1, and BCK1), chitin and mannan biosynthesis (CHS3, CHS4, CHS7, and MNN10), and ergosterol biosynthesis (ERG5 and ERG6). Four of the 20 genes (TPO1, VPS65, VPS25, and CHC1) are involved in vacuole and transport functions, 3 of the 20 genes (CCR4, POP2, and NPL3) are involved in the control of transcription, and 2 of the 20 genes are of unknown function. Disruption of nine additional genes led to CAS-IR (a fourfold increase of MIC). Five of these nine genes (SLG1, ERG3, VRP1, CSG2, and CKA2) are involved in cell wall function and signal transduction, and two of the nine genes (VPS67 and SAC2) are involved in vacuole function. To assess the specificity of susceptibility to CAS, the MICs of amphotericin B, fluconazole, flucytosine, and calcofluor for the strains were tested. Seven of 20 CAS-IS strains (with disruption of FKS1, SMI1, BCK1, CHS4, ERG5, TPO1, and ILM1) and 1 of 9 CAS-IR strains (with disruption of SLG1) demonstrated selective susceptibility to CAS. To further explore the importance of PKC in CAS susceptibility, the activity of the PKC inhibitor staurosporine in combination with CAS was tested against eight Aspergillus clinical isolates by the microdilution assay. Synergistic or synergistic-to-additive activities were found against all eight isolates by use of both MIC and minimum effective concentration endpoints.

[1]  D. E. Levin,et al.  A Second Osmosensing Signal Transduction Pathway in Yeast , 1995, The Journal of Biological Chemistry.

[2]  J. Cleary,et al.  Genome-wide Expression Profiling of the Response to Polyene, Pyrimidine, Azole, and Echinocandin Antifungal Agents in Saccharomyces cerevisiae* , 2003, Journal of Biological Chemistry.

[3]  J. Ruiz-Herrera,et al.  Chitin synthesis as target for antifungal drugs. , 2003, Current drug targets. Infectious disorders.

[4]  J. Boeke,et al.  Designer deletion strains derived from Saccharomyces cerevisiae S288C: A useful set of strains and plasmids for PCR‐mediated gene disruption and other applications , 1998, Yeast.

[5]  M. Johnston,et al.  A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Douglas,et al.  A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase , 1994, Journal of bacteriology.

[7]  D. Kelly,et al.  Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturation , 1997, FEBS letters.

[8]  S. Ishihara,et al.  Dissection of upstream regulatory components of the Rho1p effector, 1,3-beta-glucan synthase, in Saccharomyces cerevisiae. , 2002, Genetics.

[9]  Troy Ketela,et al.  Saccharomyces cerevisiae Mid2p Is a Potential Cell Wall Stress Sensor and Upstream Activator of thePKC1-MPK1 Cell Integrity Pathway , 1999, Journal of bacteriology.

[10]  T. Patterson,et al.  Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis , 2002, Antimicrobial Agents and Chemotherapy.

[11]  Ronald W. Davis,et al.  Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.

[12]  C. Douglas.  Fungal β(1,3)-d-glucan synthesis , 2001 .

[13]  S. Emr,et al.  The fungal vacuole: composition, function, and biogenesis. , 1990, Microbiological reviews.

[14]  M. Cyert,et al.  Temperature-Induced Expression of YeastFKS2 Is under the Dual Control of Protein Kinase C and Calcineurin , 1998, Molecular and Cellular Biology.

[15]  M. Jirousek,et al.  Protein kinase C inhibitors as novel anticancer drugs , 2001, Expert opinion on investigational drugs.

[16]  M. Momany,et al.  Aspergillus nidulans RhoA is involved in polar growth, branching, and cell wall synthesis. , 2004, Fungal genetics and biology : FG & B.

[17]  J. Swartz,et al.  Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.

[18]  Y. Anraku,et al.  Characterization of staurosporine-sensitive mutants of Saccharomyces cerevisiae: vacuolar functions affect staurosporine sensitivity , 2000, Molecular and General Genetics MGG.

[19]  C. Douglas.  Fungal beta(1,3)-D-glucan synthesis. , 2001, Medical mycology.

[20]  D. Kelly,et al.  Mode of Action and Resistance to Azole Antifungals Associated with the Formation of 14α-Methylergosta-8,24(28)-dien-3β,6α-diol , 1995 .

[21]  B. Daignan-Fornier,et al.  Screening the Yeast “Disruptome” for Mutants Affecting Resistance to the Immunosuppressive Drug, Mycophenolic Acid* , 2002, The Journal of Biological Chemistry.

[22]  Joseph Heitman,et al.  Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[23]  N. Morin,et al.  The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Guang-Chao Chen,et al.  Rho1p, a Yeast Protein at the Interface Between Cell Polarization and Morphogenesis , 1996, Science.

[25]  Z. Samra,et al.  In Vitro Synergy of Caspofungin and Itraconazole against Aspergillus spp.: MIC versus Minimal Effective Concentration End Points , 2003, Antimicrobial Agents and Chemotherapy.

[26]  S. Avery,et al.  Genome-Wide Screening of Saccharomyces cerevisiae To Identify Genes Required for Antibiotic Insusceptibility of Eukaryotes , 2003, Antimicrobial Agents and Chemotherapy.

[27]  D. Kontoyiannis,et al.  Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[28]  M. Kaghad,et al.  The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae , 1996, Molecular and cellular biology.

[29]  A. Parsons,et al.  Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. , 2003, Genetics.

[30]  H. Bryson,et al.  Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. , 1995, Drugs.

[31]  Yi Xing,et al.  Novel functions of the phosphatidylinositol metabolic pathway discovered by a chemical genomics screen with wortmannin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Karl Kuchler,et al.  The Yeast Protein Kinase C Cell Integrity Pathway Mediates Tolerance to the Antifungal Drug Caspofungin through Activation of Slt2p Mitogen-Activated Protein Kinase Signaling , 2003, Eukaryotic Cell.

[33]  R. Fine,et al.  Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. , 1998, Biochemical pharmacology.

[34]  D. Kontoyiannis,et al.  Overexpression of Sbe2p, a Golgi Protein, Results in Resistance to Caspofungin in Saccharomyces cerevisiae , 2002, Antimicrobial Agents and Chemotherapy.

[35]  J. Rex,et al.  In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp , 2002, Antimicrobial Agents and Chemotherapy.

[36]  K. Altendorf,et al.  Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. , 1997, The Journal of experimental biology.